BC
ACAD icon

Brinker Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Brinker Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-8,009
Closed -$338K – 931
2020
Q1 		$338K Buy
8,009
+278
+4% +$11.5K 0.01% 744
2019
Q4 		$331K Buy
7,731
+1,583
+26% +$68.9K 0.01% 812
2019
Q3 		$221K Buy
+6,148
New +$186K 0.01% 898

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Brinker Capital's ACAD Position: Q2 2020 in Review

Brinker Capital sold out of Acadia Pharmaceuticals (ACAD) in Q2 2020, closing a stake of 8,009 shares — an estimated $338K sold.

Brinker Capital first reported a position in ACAD in Q3 2019 and held it in 3 quarters. The position peaked at $338K in Q1 2020. 298 funds tracked by Wall St. Rank hold ACAD as of Q2 2020.

  • Brinker Capital reported no remaining Acadia Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
  • Brinker Capital sold 8,009 Acadia Pharmaceuticals shares in Q2 2020, an estimated $338K.
  • Brinker Capital first reported a position in Acadia Pharmaceuticals in Q3 2019 and held it in 3 quarters.
  • Brinker Capital's Acadia Pharmaceuticals position peaked at $338K in Q1 2020.
  • 298 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2020.

Based on Brinker Capital's 13F filing for Q2 2020, filed 30 Jul 2020.